Equities

Morepen Laboratories Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MOREPENLAB:NSI

Morepen Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)39.05
  • Today's Change1.13 / 2.98%
  • Shares traded1.17m
  • 1 Year change-24.29%
  • Beta0.7103
Data delayed at least 15 minutes, as of Feb 17 2026 08:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2025202520242023
ASSETS
Cash And Short Term Investments1,052169217
Total Receivables, Net3,9683,5612,978
Total Inventory5,5734,6273,946
Prepaid expenses69210145
Other current assets, total309432375
Total current assets11,5948,8907,562
Property, plant & equipment, net3,7032,3771,840
Goodwill, net745745745
Intangibles, net720197255
Long term investments1498464
Note receivable - long term867637637
Other long term assets------
Total assets17,78112,93211,105
LIABILITIES
Accounts payable3,6332,9502,269
Accrued expenses277288249
Notes payable/short-term debt460235232
Current portion long-term debt/capital leases1982111
Other current liabilities, total438526452
Total current liabilities5,0074,0203,212
Total long term debt392349.34
Total debt1,051290252
Deferred income tax702227
Minority interest3070(4.6)
Other liabilities, total443383333
Total liabilities6,2194,4603,576
SHAREHOLDERS EQUITY
Common stock1,0961,0221,022
Additional paid-in capital5,5323,6983,698
Retained earnings (accumulated deficit)5,0193,8392,877
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(84)(86)(68)
Total equity11,5628,4727,529
Total liabilities & shareholders' equity17,78112,93211,105
Total common shares outstanding548511511
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.